Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia [11]

Acta Dermato-Venereologica

Volumn 86, Issue 2, 2006, Pages 174-175

  Oztas, Pinar ^a   Erbasi, Servet ^a   Lenk, Nurdan ^a   Polat, Muhterem ^a   Han, Ozge ^a   Artuz, Ferda ^a   Alli, Nuran ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; ARTHRALGIA; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; ERYTHRODERMA; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LABORATORY TEST; LETTER; LYMPHOCYTIC INFILTRATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RASH; THROMBOCYTOPENIA; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; DERMATITIS, EXFOLIATIVE; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 33745781205     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0015     Document Type: Letter

References (8)

1. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2003; 1: 132-152.
2. Abou-Jawde R, Choueiri T, Alemany C, Mekhail T. An overview of targeted treatments in cancer. Clin Ther 2003; 25: 2121-2137.
3. Hasselbalch HC, Bjerrum OW, Jensen BA, Clausen NT, Hansen PB, Birgens H, et al. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol 2003; 74: 238-242.
4. Turkina AG, Khoroshko ND, Druzhkova GA, Zingerman BV, Zakharova ES, Chelysheva E, et al. Therapeutic efficacy of imatinib mesylate (Glivec) in chronic phase of myeloid leukemia. Ter Arkh 2003; 75: 62-67.
5. Esmaeli B, Prieto VG, Butler CE, Kim SK, Ahmadi MA, Kantarjian HM, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002; 95: 881-867.
6. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98: 2483-2487.
7. Breccia M, Latagliata R, Carmosino I, Mandelli F, Alimena G. Reactivation of porphyria cutanea tarda as a possible side effect of imatinib at high dosage in chronic myeloid leukemia. Leukemia 2004; 18: 182.
8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.